Partsch H, Stout N, Forner-Cordero I, Flour M, Moffatt C, Szuba A, Milic D, Szolnoky G, Brorson H, Abel M, Schuren J, Schingale F, Vignes S, Piller N, Döller W
Dermatology, Medical University of Vienna, Vienna, Austria.
Int Angiol. 2010 Oct;29(5):442-53.
A mainstay of lymphedema management involves the use of compression therapy. Compression therapy application is variable at different levels of disease severity. Evidence is scant to direct clinicians in best practice regarding compression therapy use. Further, compression clinical trials are fragmented and poorly extrapolable to the greater population. An ideal construct for conducting clinical trials in regards to compression therapy will promote parallel global initiatives based on a standard research agenda. The purpose of this article is to review current evidence in practice regarding compression therapy for BCRL management and based on this evidence, offer an expert consensus recommendation for a research agenda and prescriptive trials. Recommendations herein focus solely on compression interventions.
This document represents the proceedings of a session organized by the International Compression Club (ICC) in June 2009 in Ponzano (Veneto, Italy). The purpose of the meeting was to enable a group of experts to discuss the existing evidence for compression treatment in breast cancer related lymphedema (BCRL) concentrating on areas where randomized controlled trials (RCTs) are lacking.
The current body of research suggests efficacy of compression interventions in the treatment and management of lymphedema. However, studies to date have failed to adequately address various forms of compression therapy and their optimal application in BCRL. We offer recommendations for standardized compression research trials for prophylaxis of arm lymphedema and for the management of chronic BCRL. Suggestions are also made regarding; inclusion and exclusion criteria, measurement methodology and additional variables of interest for researchers to capture.
This document should inform future research trials in compression therapy and serve as a guide to clinical researchers, industry researchers and lymphologists regarding the strengths, weaknesses and shortcomings of the current literature. By providing this construct for research trials, the authors aim to support evidence-based therapy interventions, promote a cohesive, standardized and informative body of literature to enhance clinical outcomes, improve the quality of future research trials, inform industry innovation and guide policy related to BCRL.
淋巴水肿管理的主要手段包括使用压迫疗法。在疾病的不同严重程度水平上，压迫疗法的应用存在差异。关于压迫疗法的最佳实践，指导临床医生的证据很少。此外，压迫疗法的临床试验零散，难以推广至更多人群。开展压迫疗法临床试验的理想架构将促进基于标准研究议程的全球并行倡议。本文的目的是回顾目前关于压迫疗法用于乳腺癌相关淋巴水肿（BCRL）管理的实践证据，并基于此证据，为研究议程和规范性试验提供专家共识建议。本文中的建议仅聚焦于压迫干预措施。
本文档代表了国际压迫俱乐部（ICC）于2009年6月在意大利威尼托大区蓬扎诺组织的一次会议的会议记录。会议的目的是让一组专家讨论乳腺癌相关淋巴水肿（BCRL）压迫治疗的现有证据，重点关注缺乏随机对照试验（RCT）的领域。
目前的研究表明压迫干预措施在淋巴水肿的治疗和管理中具有疗效。然而，迄今为止的研究未能充分探讨各种形式的压迫疗法及其在BCRL中的最佳应用。我们为预防手臂淋巴水肿和慢性BCRL管理的标准化压迫研究试验提供建议。还就纳入和排除标准、测量方法以及研究人员感兴趣的其他变量的获取提出了建议。
本文档应为未来压迫疗法的研究试验提供参考，并作为临床研究人员、行业研究人员和淋巴学家了解当前文献的优势、劣势和不足的指南。通过提供这种研究试验架构，作者旨在支持循证治疗干预措施，促进形成一个有凝聚力、标准化且信息丰富的文献体系，以改善临床结果、提高未来研究试验的质量、为行业创新提供信息并指导与BCRL相关的政策。
